IGHE and Increased total eosinophil count: Functional studies demonstrated heightened IL-4/IL-13 responsiveness, reversed by JAK inhibition (ruxolitinib) or IL-4Rα blockade, which normalized IgE levels and tissue eosinophilia (41).